Drug-device combination therapies utilising convection-enhanced delivery (CED) are an emerging therapeutic strategy for the treatment of neurological disorders. When delivered via CED, biologics and chemotherapeutics can achieve homogeneous distribution within a targeted brain structure while avoiding systemic immunogenicity and off-target side effects. We believe that CED has the potential to transform human longevity by unlocking treatments to previously untreatable neurological disorders. At Neurochase, our goal is to develop the world's most comprehensive drug development process for CED therapeutics.